ChemoCentryx Inc logo

CCXI

ChemoCentryx Inc

$50.98

Earnings Summary

Revenue
$5.46Mn
Net Profits
$-38.61Mn
Net Profit Margins
-707.24%

Highlights

Revenue:

ChemoCentryx Inc’s revenue fell -46.6% since last year same period to $5.46Mn in the Q1 2022. On a quarterly growth basis, ChemoCentryx Inc has generated 109.08% jump in its revenue since last 3-months.

Net Profits:

ChemoCentryx Inc’s net profit fell -29.95% since last year same period to $-38.61Mn in the Q1 2022. On a quarterly growth basis, ChemoCentryx Inc has generated 4.74% jump in its net profits since last 3-months.

Net Profit Margins:

ChemoCentryx Inc’s net profit margin fell -143.35% since last year same period to -707.24% in the Q1 2022. On a quarterly growth basis, ChemoCentryx Inc has generated 54.44% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the ChemoCentryx Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.49
EPS Estimate Current Year
-0.49

Highlights

EPS Estimate Current Quarter:

ChemoCentryx Inc’s earning per share (EPS) estimates for the current quarter stand at -0.49 - a -58.06% fall from last quarter’s estimates.

EPS Estimate Current Year:

ChemoCentryx Inc’s earning per share (EPS) estimates for the current year stand at -0.49.

Key Ratios

Key ratios of the ChemoCentryx Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.55
Return on Assets (ROA)
-0.19
Return on Equity (ROE)
-0.47
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

ChemoCentryx Inc’s earning per share (EPS) fell -27.91% since last year same period to -0.55 in the Q1 2022. This indicates that the ChemoCentryx Inc has generated -27.91% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. ChemoCentryx Inc’s return on assets (ROA) stands at -0.19.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. ChemoCentryx Inc’s return on equity (ROE) stands at -0.47.

Dividend Per Share (DPS):

ChemoCentryx Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.31
-0.55
-77.42%

Company Information

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Organisation
ChemoCentryx Inc
Headquarters
Mountain View, California, US
Employees
133
Industry
Health Technology
CEO
Thomas Schall